NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$84.11

+0.08 (+0.10%)

(As of 12/8/2022 12:00 AM ET)

Add

Compare

Today's Range: $83.52
▼
$84.58
50-Day Range: $66.64
▼
$84.11
52-Week Range: $64.32
▼
$84.86

Volume: 1.02 million shs
Average Volume: 1.51 million shs
Market Capitalization: $18.71 billion

P/E Ratio: 21.40
Dividend Yield: N/A
Price Target: $84.20

Incyte MarketRank™ Forecast

Analyst Rating: Hold
2.13 Rating Score
Upside/Downside: 0.1% Upside
$84.20 Price Target
Short Interest: Healthy
3.16% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.19
Upright™ Environmental Score
News Sentiment: 0.39
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 55.61%
From $2.14 to $3.33 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

130th out of 1,022 stocks

Commercial Physical Research Industry

4th out of 18 stocks

2.1

Analyst's Opinion

Consensus Rating
Incyte has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 2 buy ratings, 5 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $84.20, Incyte has a forecasted upside of 0.1% from its current price of $84.11.
Amount of Analyst Coverage
Incyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
3.16% of the outstanding shares of Incyte have been sold short.
Short Interest Ratio / Days to Cover
Incyte has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Incyte has recently decreased by 15.89%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Incyte does not currently pay a dividend.
Dividend Growth
Incyte does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Incyte has received a 70.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Pharmacovigilance services", and "Clinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Incyte is -1.19.

1.9

News and Social Media Coverage

News Sentiment
Incyte has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Incyte this week, compared to 7 articles on an average week.
Search Interest
Only 3 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
MarketBeat Follows
8 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Incyte insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.74% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Incyte are expected to grow by 55.61% in the coming year, from $2.14 to $3.33 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Incyte is 21.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of Incyte is 21.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.62.
Price to Earnings Growth Ratio
Incyte has a PEG Ratio of 1.72. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Incyte has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

December 4, 2022 | americanbankingnews.com

Incyte Co. (NASDAQ:INCY) Sees Large Decline in Short Interest

December 3, 2022 | americanbankingnews.com

Analysts Set Incyte Co. (NASDAQ:INCY) Price Target at $82.50

December 2, 2022 | finance.yahoo.com

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

November 7, 2022 | finance.yahoo.com

Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

November 7, 2022 | finance.yahoo.com

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

November 2, 2022 | seekingalpha.com

Incyte A Buy As Revenue From Opzelura Ramps

October 25, 2022 | finance.yahoo.com

Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline

October 20, 2022 | finance.yahoo.com

Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology - Yahoo Finance

October 19, 2022 | businesswire.com

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine - Business Wire

October 19, 2022 | finance.yahoo.com

Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors - Yahoo Finance

October 18, 2022 | benzinga.com

Expert Ratings for Incyte - Incyte (NASDAQ:INCY) - Benzinga

October 18, 2022 | finance.yahoo.com

Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' - Yahoo Finance

October 17, 2022 | bizjournals.com

MacroGenics strikes deal with Gilead Sciences - Washington Business Journal - The Business Journals

October 17, 2022 | nasdaq.com

Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now - Nasdaq

October 17, 2022 | nasdaq.com

Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes" - Nasdaq

October 16, 2022 | finance.yahoo.com

Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine - Yahoo Finance

October 15, 2022 | nasdaq.com

Friday Sector Leaders: Healthcare, Consumer Products - Nasdaq

October 13, 2022 | thestreet.com

Is Incyte Building a Vitiligo Empire? - TheStreet

October 11, 2022 | finance.yahoo.com

Esophageal Cancer Clinical Trial Pipeline Insights Featuring 80+ Companies | DelveInsight - Yahoo Finance

October 9, 2022 | finance.yahoo.com

The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma - Yahoo Finance

October 7, 2022 | benzinga.com

Knight Therapeutics Late Thursday Announces Regulatory Submission For Tafasitamab In Brazil - Incyte (NASDAQ:INCY) - Benzinga

October 7, 2022 | benzinga.com

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil - Incyte (NASDAQ:INCY) - Benzinga

October 3, 2022 | benzinga.com

Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases

October 3, 2022 | finance.yahoo.com

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

September 29, 2022 | seekingalpha.com

Incyte Stock: Improving Growth Prospects And Favorable Chart - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings: 11/01/2022
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/14/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:INCY
CUSIP: 45337C10
CIK: 879169
Web: www.incyte.com
Phone: (302) 498-6700
Fax: 302-425-2750
Employees: 2,094
Year Founded: 1991

Price Target and Rating

Average Stock Price Forecast: $84.20
High Stock Price Forecast: $108.00
Low Stock Price Forecast: $63.00
Forecasted Upside/Downside: +0.1%
Consensus Rating: Hold
Rating Score (0-4): 2.13
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.93
Trailing P/E Ratio: 21.40
Forward P/E Ratio: 39.30
P/E Growth: 1.72
Net Income: $948.58 million
Net Margins: 26.30%
Pretax Margin: 17.07%
Return on Equity: 9.04%
Return on Assets: 6.92%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 3.80
Quick Ratio: 3.75

Sales & Book Value

Annual Sales: $2.99 billion
Price / Sales: 6.27
Cash Flow: $2.42 per share
Price / Cash Flow: 34.71
Book Value: $17.07 per share
Price / Book: 4.93

Miscellaneous

Outstanding Shares: 222,475,000
Free Float: 183,542,000
Market Cap: $18.71 billion
Optionable: Optionable
Beta: 0.72

Social Links

Key Executives

Mr. Herve Hoppenot (Age 62)
Chairman, Pres & CEO
Comp: $2.36M

Ms. Christiana Stamoulis MBA (Age 51)
Exec. VP & CFO
Comp: $967.48k

Ms. Maria E. Pasquale (Age 56)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $867.6k

Dr. Barry P. Flannelly M.B.A. (Age 64)
MBA, Pharm.D., Exec. VP & GM of North America
Comp: $842.85k

Dr. Steven H. Stein M.D. (Age 55)
Exec. VP & Chief Medical Officer
Comp: $983.84k

Mr. Thomas Tray (Age 44)
VP of Fin., Chief Accounting Officer & Controller

Mr. Michael James Morrissey (Age 58)
Exec. VP & Head of Global Technical Operations

Dr. Dashyant Dhanak Ph.D. (Age 61)
Exec. VP & Chief Scientific Officer

Ms. Christine Chiou
Head of Investor Relations

Ms. Pamela M. Murphy (Age 71)
VP of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings or view top-rated stocks.
What is Incyte's stock price forecast for 2023?: 8 brokerages have issued twelve-month price objectives for Incyte's stock. Their INCY share price forecasts range from $63.00 to $108.00. On average, they anticipate the company's stock price to reach $84.20 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for INCY or view top-rated stocks among Wall Street analysts.
How have INCY shares performed in 2022?: Incyte's stock was trading at $73.40 at the beginning of the year. Since then, INCY shares have increased by 14.6% and is now trading at $84.11.
View the best growth stocks for 2022 here.
Are investors shorting Incyte?: Incyte saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 7,040,000 shares, a decrease of 15.9% from the October 31st total of 8,370,000 shares. Based on an average daily trading volume, of 1,400,000 shares, the days-to-cover ratio is currently 5.0 days.
View Incyte's Short Interest.
When is Incyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our INCY earnings forecast.
How were Incyte's earnings last quarter?: Incyte Co. (NASDAQ:INCY) issued its earnings results on Tuesday, November, 1st. The biopharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.54 by $0.10. The biopharmaceutical company earned $823.30 million during the quarter, compared to analyst estimates of $847 million. Incyte had a net margin of 26.30% and a trailing twelve-month return on equity of 9.04%.

What is Hervé Hoppenot's approval rating as Incyte's CEO?: 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Incyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).
What is Incyte's stock symbol?: Incyte trades on the NASDAQ under the ticker symbol "INCY."
Who are Incyte's major shareholders?: Incyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.54%), BlackRock Inc. (8.83%), State Street Corp (4.29%), Royal Bank of Canada (4.14%), Renaissance Technologies LLC (2.18%) and Bellevue Group AG (1.23%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends.
How do I buy shares of Incyte?: Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Incyte's stock price today?: One share of INCY stock can currently be purchased for approximately $84.11.
How much money does Incyte make?: Incyte (NASDAQ:INCY) has a market capitalization of $18.71 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $3.93 on an earnings per share basis.
How many employees does Incyte have?: The company employs 2,094 workers across the globe.
How can I contact Incyte?: Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial